Edgewise Therapeutics (EWTX) Other Non-Current Liabilities (2021 - 2022)

Edgewise Therapeutics (EWTX) reported Other Non-Current Liabilities of $192000.0 for Q2 2022, up 2.67% sequentially from $187000.0 in Q1 2022.

Edgewise Therapeutics (EWTX) Other Non-Current Liabilities (2021 - 2022) Analysis & Trends

Edgewise Therapeutics (EWTX) has 2 years of Other Non-Current Liabilities data on file, last reported at $192000.0 in Q2 2022.

For the quarter ending Q2 2022, Other Non-Current Liabilities changed N/A year-over-year to $192000.0; the trailing twelve-month figure through Jun 2022 stood at $192000.0 (changed N/A YoY), and the FY2021 full-year result was $329000.0, changed N/A from the prior year.
Other Non-Current Liabilities advanced to $192000.0 in Q2 2022, from $187000.0 in the prior quarter.
In the past five years, Other Non-Current Liabilities ranged from a high of $329000.0 in Q4 2021 to a low of $187000.0 in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Edgewise Therapeutics	4.21 Bn	4.21 Bn	-

Download Data